Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,615
datasets available to search
ShareScore release 0.9.0
Dataset results
2,615 results for “HIV Infections”
Data from: Factors associated with pulmonary impairment in HIV-infected South African adults
Background: HIV-infected individuals have increased risk of developing obstructive lung disease (OLD). Studies from developed countries report high viral load, low CD4 counts, and anti-retroviral therapy (ART) to be associated with OLD; but these findings may not be generalizable to populations in resource-limited settings. Methods: We conducted a prospective cohort study of lung function in 730 HIV-infected black South African adults. Pre-bronchodilator spirometry was performed at enrollment and repeated annually for three years. Logistic regression models were used to identify factors associated with OLD, defined as FEV1/FVC<0.70, at enrollment. Excess annual declines in FEV1 and FVC were modelled as the product-term of follow-up time and exposures using random effects regression. Results: Median (IQR) age at enrollment was 36 (32-41) years, 85% were female and 30% ever-smoked with a median (IQR) exposure of 3 (1-6) pack-years. Median (IQR) CD4 count and viral load at enrollment were 372 (261-518) cells/mm3 and 2655 (91-13,548) copies/mL respectively. Overall, 25% were receiving ART at enrollment, 16% of whom reported at least 6 months of ART receipt. OLD was found in 35 (5%) at enrollment. Increasing age (aOR=2.08 per 10-years [95%CI 1.22-3.57], p=0.007), current smoking (aOR=3.55 [95%CI 1.20-10.53], p=0.02), and CRP (aOR=1.01 per unit-increase [95%CI 1.00-1.03], p=0.04) were significantly associated with OLD at enrollment; while increasing CD4 count (aOR=1.02 per-100 cells/mm3 [95%CI 0.85-1.22], p=0.82), viral load (aOR=0.67 per log-increase [95%CI 0.43-1.10], p=0.12) and receipt of ART (aOR=0.57 [95%CI 0.18-1.75], p=0.32) were not. The median (IQR) follow-up time was 18 (12-24) months. Participants with a history of tuberculosis (TB) had a 35 mL (95%CI 2-68, p=0.03) and 57 mL (95%CI 19-96, p=0.003) per year excess loss of FEV1 and FVC respectively. Conclusion: Prevalent OLD was associated with older age, current smoking and higher CRP levels, but not CD4 counts and ART, in HIV-infected South African adults. Better understanding of the long-term effects of TB, smoking and inflammation on lung function in HIV-infected populations is urgently needed.
Data from: Clinical factors associated with long-term complete remission versus poor response to chemotherapy in HIV-infected children and adolescents with Kaposi sarcoma receiving bleomycin and vincristine: a retrospective observational study
Kaposi sarcoma (KS) is the most common HIV-associated malignancy in children and adolescents in Africa. Pediatric KS is distinct from adult disease. We evaluated the clinical characteristics associated with long-term outcomes. We performed a retrospective observational analysis of 70 HIV-infected children and adolescents with KS less than 18 years of age diagnosed between 8/2010 and 6/2013 in Lilongwe, Malawi. Local first-line treatment included bleomycin and vincristine plus nevirapine-based highly active anti-retroviral therapy (HAART). Median age was 8.6 years (range 1.7–17.9); there were 35 females (50%). Most common sites of presentation were: lymph node (74%), skin (59%), subcutaneous nodules (33%), oral (27%), woody edema (24%), and visceral (16%). Eighteen (26%) presented with lymphadenopathy only. Severe CD4 suppression occurred in 28%. At time of KS diagnosis, 49% were already on HAART. Overall, 28% presented with a platelet count < 100 x 109/L and 37% with hemoglobin < 8 g/dL. The 2-year event-free (EFS) and overall survival (OS) were 46% and 58% respectively (median follow-up 29 months, range 15–50). Multivariable analysis of risk of death and failure to achieve EFS demonstrated that visceral disease (odds ratios [OR] 19.08 and 11.61, 95% CI 2.22–163.90 and 1.60–83.95 respectively) and presenting with more than 20 skin/oral lesions (OR 9.57 and 22.90, 95% CI 1.01–90.99 and 1.00–524.13 respectively) were independent risk factors for both. Woody edema was associated with failure to achieve EFS (OR 7.80, 95% CI 1.84–33.08) but not death. Univariable analysis revealed that lymph node involvement was favorable for EFS (OR 0.28, 95% CI 0.08–0.99), while T1 TIS staging criteria, presence of cytopenias, and severe immune suppression were not associated with increased mortality. Long-term complete remission is achievable in pediatric KS, however outcomes vary according to clinical presentation. Based on clinical heterogeneity, treatment according to risk-stratification is necessary to improve overall outcomes.
GW873140 In Combination With Kaletra In HIV Infected Subjects
ClinicalTrials.gov study NCT00102778. IPD Sharing: Not stated. Countries: 10. Publications: 0.
IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV Infection
ClinicalTrials.gov study NCT01942655. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients
ClinicalTrials.gov study NCT01201239. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Identifying Undiagnosed Asymptomatic HIV Infection in Hispanic/Latino Adolescents and Young Adults
ClinicalTrials.gov study NCT01203332. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Study of Genetic Polymorphisms in Thai HIV-1 Infected Patients on SQV/r
ClinicalTrials.gov study NCT00476502. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Protocol RV 583 Multinational Observational Cohort of HIV and Other Infections
ClinicalTrials.gov study NCT05147519. IPD Sharing: NO. Countries: 3. Publications: 0.
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection
ClinicalTrials.gov study NCT00002176. IPD Sharing: Not stated. Countries: 1. Publications: 0.
PK TDF in Thai HIV-infected Children
ClinicalTrials.gov study NCT02404259. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety and Efficacy of Zinc Supplementation in HIV-1-Infected Children in South Africa
ClinicalTrials.gov study NCT00138047. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Immunity at the Genital Mucosa of HIV-1 Infected and Healthy Women
ClinicalTrials.gov study NCT01715103. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3
ClinicalTrials.gov study NCT00001064. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection
ClinicalTrials.gov study NCT00000875. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia
ClinicalTrials.gov study NCT00797381. IPD Sharing: Not stated. Countries: 1. Publications: 0.
First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers
ClinicalTrials.gov study NCT01719627. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1
ClinicalTrials.gov study NCT00781287. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Evaluating an Exercise Program to Reduce Cardiovascular Risk Factors in Children Infected With HIV
ClinicalTrials.gov study NCT00908284. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Pilot Study of Metabolic Syndromes and HIV Infections in Indian Tibetans
ClinicalTrials.gov study NCT01261221. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Assisting HIV-infected Mothers in Disclosing Their Serostatus to Their Children
ClinicalTrials.gov study NCT00429546. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.